Identifying Distinct Molecular Subtypes and Establishing a Prognostic Framework for DLBCL Patients via Multiomics Analysis and Machine Learning Approaches
Human Mutation · 2026-01 · 2026 (1)
DOI: 10.1155/humu/7614954 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Mutation, online erschienen am 06.07.2026. Verfasst von Hongyu Shen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China, jsph.net. Hauptthemen laut MEDLINE: Machine Learning, Lymphoma, Large B-Cell, Diffuse. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Diffuse large B‐cell lymphoma (DLBCL) is characterized by profound heterogeneity that underpins varied clinical outcomes. To decipher this complexity, we performed an integrated single‐cell and genomic analysis. Using scRNA‐seq data (GSE182434), we identified six distinct malignant B‐cell subclusters (MB1‐MB6) within the DLBCL ecosystem. Cell–cell communication analysis revealed intricate interaction networks, particularly involving the MIF and Complement pathways. Prognostic analysis of bulk transcriptomic data (GSE32918) identified the MB5‐related gene signature as the most critical factor associated with poor overall survival. This MB5 subgroup was associated with enhanced proliferative processes, a higher tumor mutational burden, and specific comutations. Leveraging MB5 marker genes, we developed and validated a robust CoxBoost‐RSF machine‐learning model that effectively stratified patient risk in independent cohorts. Our study defines the MB5 malignant B‐cell subgroup as a key driver of DLBCL aggressiveness and provides both a novel prognostic biomarker and a framework for personalized therapeutic targeting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, The First Affiliated Hospital With Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China, jsph.net.
- Jiangsu Province Engineering Research Center of Cell and Gene Therapy for hematologic and lymphoid Diseases, Nanjing, Jiangsu, China.
- Department of Hematology, Yancheng No. 1 People's Hospital, Yancheng, Jiangsu, China.
- Department of Oncology, Huai'an Hospital of Hua'an City, Huai'an Cancer Hospital, Huai'an, Jiangsu, China.
- Department of Cell and Molecular Biology, Karolinska Institutet, Stockholm, Sweden, ki.se.
- Department of Oncology, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin, Jiangsu, China.
ORCID-Profile: Xiao Liang, Lei Fan
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Shen, H., Lu, J., Yan, Q., Chou, J., Liang, X., Fan, W., & Fan, L. (2026). Identifying Distinct Molecular Subtypes and Establishing a Prognostic Framework for DLBCL Patients via Multiomics Analysis and Machine Learning Approaches. Human Mutation, 2026(1). https://doi.org/10.1155/humu/7614954
Vancouver
Shen H, Lu J, Yan Q, Chou J, Liang X, Fan W, et al. Identifying Distinct Molecular Subtypes and Establishing a Prognostic Framework for DLBCL Patients via Multiomics Analysis and Machine Learning Approaches. Human Mutation. 2026;2026(1). doi:10.1155/humu/7614954
BibTeX
@article{Shen2026,
author = {Shen, Hongyu and Lu, Jinbo and Yan, Qi and Chou, Jinjiang and Liang, Xiao and Fan, Weifei and Fan, Lei},
title = {Identifying Distinct Molecular Subtypes and Establishing a Prognostic Framework for DLBCL Patients via Multiomics Analysis and Machine Learning Approaches},
journal = {Human Mutation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/humu/7614954}
}
EUVIMED